PCA
SNDX icon

Pallas Capital Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

Pallas Capital Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Sell
9,716
-1,269
-12% -$27.6K 0.01% 726
2025
Q4 		$231K Buy
10,985
+875
+9% +$15.3K 0.01% 770
2025
Q3 		$156K Buy
+10,110
New +$132K 0.01% 804

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Pallas Capital Advisors's SNDX Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Syndax Pharmaceuticals (SNDX) stake by 12% in Q1 2026, selling an estimated $27.6K and leaving 9,716 shares worth $227K. The position accounts for 0.01% of the portfolio, ranked #726.

Pallas Capital Advisors first reported a position in SNDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $231K in Q4 2025. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Pallas Capital Advisors held 9,716 shares of Syndax Pharmaceuticals worth $227K as of Q1 2026.
  • Pallas Capital Advisors sold 1,269 Syndax Pharmaceuticals shares in Q1 2026, an estimated $27.6K.
  • Syndax Pharmaceuticals made up 0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #726 holding.
  • Pallas Capital Advisors first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Pallas Capital Advisors's Syndax Pharmaceuticals position peaked at $231K in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.